{"data":{"id":"10.6084/m9.figshare.1100173","type":"dois","attributes":{"doi":"10.6084/m9.figshare.1100173","prefix":"10.6084","suffix":"m9.figshare.1100173","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Ramirez, Jorge H","nameType":"Personal","givenName":"Jorge H","familyName":"Ramirez","affiliation":[],"nameIdentifiers":[{"schemeUri":"https://orcid.org","nameIdentifier":"https://orcid.org/0000-0001-6176-2816","nameIdentifierScheme":"ORCID"}]},{"name":"Atanasov, Atanas G.","nameType":"Personal","givenName":"Atanas G.","familyName":"Atanasov","affiliation":[],"nameIdentifiers":[]},{"name":"Bravo, Paco","nameType":"Personal","givenName":"Paco","familyName":"Bravo","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"Reanalysis of JUPITER clinical trial (NCT00239681)- Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events"}],"publisher":"figshare","container":{},"publicationYear":2014,"subjects":[{"subject":"Statistics"},{"subject":"FOS: Mathematics","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Mathematics","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Medicine"},{"subject":"Diseases"},{"subject":"Pharmacology"}],"contributors":[],"dates":[{"date":"2014-07-11","dateType":"Created"},{"date":"2015-12-02","dateType":"Updated"},{"date":"2014","dateType":"Issued"}],"language":null,"types":{"ris":"DATA","bibtex":"misc","citeproc":"dataset","schemaOrg":"Dataset","resourceType":"Dataset","resourceTypeGeneral":"Dataset"},"relatedIdentifiers":[],"relatedItems":[],"sizes":["557841 Bytes"],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":"Table: Reanalysis of adverse events\u003cbr\u003eNCT00239681: JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events Chi-square statistics ______ 1. Not all adverse drug reactions are included in this Table. 2. Adverse events appear to be much higher than 18%. (1) 3. Results available at ClinicalTrials.gov for the JUPITER study are not consistent with publications reporting the results of this trial. http://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00239681 For example: Discordance between results reported in the number of patients diagnosed with diabetes mellitus. 1. ClinicalTrials.gov: Placebo=13; Rosuvastatin=14 | 2. Article (PMID: 22883507): Placebo=216; Rosuvastatin=270) 4. Primary outcome was modified in the registry history available at ClinicalTrials.gov http://clinicaltrials.gov/archive/NCT00239681/2014_03_21/changes 5. It is not clear why this study was terminated. \u003cstrong\u003eMarch 13, 2008.\u003c/strong\u003e \u003cbr\u003e\u003cem\u003e\"Independent Data Monitoring Committee for JUPITER met and agreed that the studyshould continue as planned.\"\u003c/em\u003e \u003cstrong\u003eApril 2, 2008.\u003c/strong\u003e\u003cem\u003e \u003cbr\u003e\"AstraZeneca announced it has decided to stop the CRESTOR JUPITER clinicalstudy early based on a recommendation from an Independent Data Monitoring Boardand the JUPITER Steering Committee, which met on March 29, 2008. The study willbe stopped early because there is unequivocal evidence of a reduction incardiovascular morbidity and mortality amongst patients who received CRESTOR when compared to placebo.\"\u003c/em\u003e http://clinicaltrials.gov/archive/NCT00239681/2008_04_02/changes \u003cstrong\u003eReferences\u003c/strong\u003e 1. Should people at low risk of cardiovascular disease take a statin? BMJ 2014; 348:g3329","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"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","url":"https://figshare.com/articles/dataset/Table_Reanalysis_of_adverse_events_JUPITER_clinical_trial_NCT00239681_Crestor_20mg_Versus_Placebo_in_Prevention_of_Cardiovascular_CV_Events/1100173","contentUrl":null,"metadataVersion":2,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2014-07-24T00:34:12.000Z","registered":"2014-07-24T00:34:13.000Z","published":"2014","updated":"2020-09-04T22:21:57.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.1100173","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}